MOUNTAIN VIEW, Calif.--(BUSINESS WIRE)--VIVUS, Inc. (NASDAQ: VVUS), a pharmaceutical company dedicated to the development and commercialization of novel therapeutic products, today announced that Dr. Kishore Gadde presented the positive results of the Quality of Life data collected during the phase 2 clinical trial of Qnexa at the North America Association of the Study of Obesity (NAASO) 2007 Annual Scientific Meeting in New Orleans, LA. The poster presentation was entitled “Changes in Weight and Quality of Life in Obese Adults Treated with Topiramate plus Phentermine.” The poster (number 272-P) was presented during the poster viewing session on Sunday, October 21, 2007.
